Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS

The third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), osimertinib, aumolertinib, and furmonertinib represent a new treatment option for patients with EGFR p.Thr790 Met (T790 M)-mutated non-small cell lung cancer (NSCLC). Currently, there are no studies reporti...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Meng, Lu, Ma, Yinling, Li, Yajing, Xing, Xiaoqing, Guo, Caihui, Dong, Zhanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325192/
https://www.ncbi.nlm.nih.gov/pubmed/35889345
http://dx.doi.org/10.3390/molecules27144474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325192/
https://www.ncbi.nlm.nih.gov/pubmed/35889345
http://dx.doi.org/10.3390/molecules27144474

Ejemplares similares